36 72

Cited 0 times in

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer

 Junsik Park  ;  Kyung Jin Eoh  ;  Eun Ji Nam  ;  Sunghoon Kim  ;  Sang Wun Kim  ;  Young Tae Kim  ;  Jung Yun Lee 
 YONSEI MEDICAL JOURNAL, Vol.61(4) : 284-290, 2020-04 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols / adverse effects ; Antineoplastic Combined Chemotherapy Protocols / therapeutic use* ; Bevacizumab / administration & dosage ; Bevacizumab / therapeutic use* ; CA-125 Antigen ; Carboplatin / administration & dosage ; Carboplatin / therapeutic use ; Carcinoma, Ovarian Epithelial / mortality ; Carcinoma, Ovarian Epithelial / pathology ; Carcinoma, Ovarian Epithelial / therapy* ; Cytoreduction Surgical Procedures / adverse effects ; Cytoreduction Surgical Procedures / mortality ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy* ; Neoplasm Staging ; Ovarian Neoplasms / mortality ; Ovarian Neoplasms / pathology ; Ovarian Neoplasms / therapy* ; Paclitaxel / administration & dosage ; Paclitaxel / therapeutic use ; Postoperative Complications ; Retrospective Studies ; Survival Analysis ; Treatment Outcome
Bevacizumab ; epithelial ovarian cancer ; interval debulking surgery ; neoadjuvant chemotherapy
Purpose: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improve clinical outcomes without affecting safety. Materials and methods: We retrospectively reviewed medical records of patients with pathologically confirmed ovarian cancer who received neoadjuvant chemotherapy (NAC) at Yonsei Cancer Hospital. We divided the patients into groups based on the use of bevacizumab for NAC (CP group: carboplatin+paclitaxel vs. BCP group: bevacizumab+carboplatin+paclitaxel) and compared patient characteristics, responses to NAC, and surgical and survival outcomes between the two groups. Overall, 88 patients in the CP group and 16 patients in the BCP group received NAC. The primary endpoint was survival outcomes. Complete resection rate after interval debulking surgery (IDS), cancer antigen 125 (CA-125) normalization after NAC, and chemotherapy response score were secondary endpoints. Results: After NAC treatment, all patients underwent IDS. There were no significant differences in adverse events during NAC or postoperative complications between the two groups (p=0.293 and p=0.485, respectively). There were also no significant differences in CA-125 normalization after NAC (42.0% vs. 43.8%, p=0.899) or complete resection rate after IDS (47.7% vs. 56.3%, p=0.530). However, although the BCP group did not show longer overall survival (OS) (log-rank p=0.854), they had significantly longer progression-free survival (PFS) than the CP group (log-rank p=0.048). Conclusion: Bevacizumab-containing NAC might be safe and provide longer PFS than chemotherapy alone in patients with advanced ovarian cancer. However, further study is necessary to investigate the impact of bevacizumab-containing NAC on OS.
Files in This Item:
T202004779.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sang Wun(김상운) ORCID logo https://orcid.org/0000-0002-8342-8701
Kim, Sung Hoon(김성훈) ORCID logo https://orcid.org/0000-0002-1645-7473
Kim, Young Tae(김영태) ORCID logo https://orcid.org/0000-0002-7347-1052
Nam, Eun Ji(남은지) ORCID logo https://orcid.org/0000-0003-0189-3560
Park, Junsik(박준식)
Eoh, Kyung Jin(어경진) ORCID logo https://orcid.org/0000-0002-1684-2267
Lee, Jung-Yun(이정윤) ORCID logo https://orcid.org/0000-0001-7948-1350
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.